Acute Kidney Injury after Cardiac Surgery: Risk Factors and Novel Biomarkers

Shi-Min Yuan¹, MD, PhD

Abstract

Acute kidney injury (AKI) is a common and severe complication after cardiac surgery. Currently, a series of novel biomarkers have favored the assessment of AKI after cardiac surgery in addition to the conventional indicators. The biomarkers, such as urinary liver fatty acid binding protein (L-FABP), urinary neutrophil gelatinase-associated lipocalin (NGAL), serum L-FABP, heart-type FABP, kidney injury molecule 1 (KIM-1), and interleukin-18 were found to be significantly higher in patients who developed AKI after cardiac surgery than those who did not. Apart from urinary interleukin-18, the novel biomarkers have been recognized as reliable indicators for predicting the diagnosis, adverse outcome, and even mortality of AKI after cardiac surgery. The timing of the renal replacement therapy is a significant predictor relating to patients’ prognoses. In patients with AKI after cardiac surgery, renal replacement therapy should be performed as early as possible in order to achieve promising outcomes. In children, AKI after cardiac surgery can be managed with peritoneal dialysis. AKI after cardiac surgery has received extensive attention as it may increase early mortality and impact long-term survival of patients as well. The purpose of this article was to analyze the changes of the pertinent biomarkers, to explore the related risk factors leading to the occurrence of AKI after cardiac surgery, and to provide a basis for the clinical prevention and reduction of AKI.

Keywords: Acute Kidney Injury. Biomarkers. Dialysis. Renal Replacement Therapy. Risk Factors.

Abbreviations, acronyms & symbols

| Abbreviation | Definition |
|--------------|------------|
| ACEI         | Angiotensin-converting enzyme inhibitor |
| AKI          | Acute kidney injury |
| AKIN         | Acute Kidney Injury Network |
| ARB          | Angiotensin II receptor antagonist |
| AUC          | Area under curve |
| BP           | Blood pressure |
| CABG         | Coronary artery bypass grafting |
| CPB          | Cardiopulmonary bypass |
| eGFR         | Estimated glomerular filtration rate |
| GDF-15       | Growth-differentiation factor-15 |
| GFR          | Glomerular filtration rate |
| h-FABP       | Heart-type fatty acid binding protein |
| IGFBP7       | Insulin-like growth factor binding protein 7 |
| IL           | Interleukin |
| KDIGO        | Kidney Disease Improving Global Outcomes |
| KIM-1        | Kidney injury molecule 1 |
| L-FABP       | Liver-type fatty acid binding protein |
| NAC          | N-acetylcysteine |
| NGAL         | Neutrophil gelatinase-associated lipocalin |
| RAS          | Renin-angiotensin system |
| RIFLE        | Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease |
| SAS          | Sympathetic-adrenomedullary system |
| SCr          | Serum creatinine |
| TIMP-2       | Tissue inhibitor of metalloproteinases-2 |
| USA          | United States of America |

¹Department of Cardiothoracic Surgery, The First Hospital of Putian, Teaching Hospital, Fujian Medical University, Putian, Fujian Province, People’s Republic of China.

This study was carried out at The First Hospital of Putian, Teaching Hospital, Fujian Medical University, People’s Republic of China.

DOI: 10.21470/1678-9741-2018-0212

Braz J Cardiovasc Surg 2019;34(3):352-360

Article received on July 22nd, 2018.
Article accepted on October 8th, 2018.

Correspondence Address:
Shi-Min Yuan
https://orcid.org/0000-0002-1773-2959
389 Longdejing Street, Chengxiang District, Putian, Fujian Province, People’s Republic of China
Zip code: 351100
E-mail: shiminyuan126.com
INTRODUCTION

Acute kidney injury (AKI) is a common and severe complication after cardiac surgery with an incidence of 3.4% to 1.9% of which requiring dialysis treatment[1]. The incidences of AKI in patients receiving isolated conventional coronary artery bypass grafting (CABG) and off-pump coronary artery bypass are 2.9% and 1.4%, respectively, with 35.8% (19/53) of the 49 AKI patients requiring dialysis[2]. A large nationwide database analysis in the United States revealed that CABG-associated AKI needing dialysis had increased from 0.2% to 0.6%, while the mortality simultaneously decreased from 47.4% in 1988, to 29.7% in 2003[3]. In a retrospective cohort study of patients undergoing CABG in a single hospital in Brazil, the incidence of postoperative AKI was 9.3%[4]. The incidence of AKI was much higher in patients receiving CABG older than 70 years than in younger patients[5]. The incidence of AKI was much higher in patients with conventional aortic valve replacement than in those with transcatheter aortic valve implantation[6]. Postoperative AKI not only extends the hospitalization days and increases the expenses of the patients, but also becomes an important independent prognostic risk factor. Especially, the incidence of AKI in patients after operation for thoracic aortic dissection is relatively high, with an increased mortality[7]. It was reported that a total of 27.7% of postoperative AKI patients developed atrial fibrillation[8]. Novel biomarkers that are applied in clinical practice as early and rapid indicators of AKI after cardiac surgery greatly facilitated the assessments of the occurrence, progression, and prognosis of the patients. AKI after cardiac surgery has received extensive attention as it may increase early mortality and impact long-term survival of patients as well. The purpose of this study was to analyze the changes of the pertinent biomarkers, to explore the related risk factors leading to the occurrence of AKI, and to provide a basis for the clinical prevention and reduction of AKI.

DEFINITIONS

The diagnosis of AKI was based on: 1) gradually decreased urine output <0.5 mL/kg/hour, for consecutively three hours with a poor response to diuretics; and 2) plasma creatinine >110 µmol/L or exceeding the baseline for over >50%[9]. Severe renal insufficiency is defined as an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m^2[10]. The diagnostic criteria of AKI following cardiac surgery are a 0.3 mg/dL or 50% or higher change in serum creatinine from baseline or a reduction on urine output of <0.5 mL/kg/hour over a six-hour interval, within 48 hours, following adequate volume resuscitation[11]. In addition, the eGFR by inclusion of cystatin C, named as Formula of Larsson, and calculated as 99.43 × cystatin C^-1.5837 can be a more sensitive indicator of renal function after cardiac surgery in comparison to creatinine and the glomerular filtration rate (GFR) per se[12].

The Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) classification, the Acute Kidney Injury Network (AKIN)[13], and the Kidney Disease Improving Global Outcomes (KDIGO) stages[14] are practical predictors for the evaluation of AKI after CABG and (or) heart valve operations (Table 1). The Society of Thoracic Surgeons scoring system can

| Table 1. Classification systems for acute kidney injury. |
| --- | --- | --- |
| I: RIFLE Classification |  |
| Stage | GFR criteria | Urine output criteria |
| Risk | SCR increased 1.5-2 times baseline or GFR decreased >25% | <0.5 mL/kg/hour for <6 hours |
| Injury | SCR increased 2-3 times baseline or GFR decreased >50% | <0.5 mL/kg/hour for >12 hours |
| Failure | SCR increased ≥3 times baseline or GFR decreased 75% or SCR ≥4 mg/dL; acute rise ≥0.5 mg/dL | <0.3 mL/kg/hour for 24 hours (oliguria) or anuria for 12 hours |
| Loss of function | Persistent acute renal failure: complete loss of kidney function >4 weeks (requiring dialysis) | |
| End-stage renal disease | Complete loss of kidney function >3 months (requiring dialysis) | |
| II. Acute Kidney Injury Network (AKIN) |  |
| Abrupt (within 48 hours) reduction in kidney function currently defined as an absolute increase in SCR of 0.3 mg/dL or more (≥26.4 µmol/L) or A percentage increase in SCR of 50% or more (1.5-fold from baseline) or A reduction in urine output (documented oliguria of <0.5 mL/kg/hour for >6 hours) |  |
| III. Kidney Disease Improving Global Outcomes (KDIGO) |  |
| Increase in SCR by 0.3 mg/dL or more within 48 hours or Increase in SCR to 1.5 times baseline or more within the last 7 days or Urine output <0.5 mL/kg/hour for 6 hours |  |

GFR=glomerular filtration rate; RIFLE=Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease; SCR=serum creatinine
be used for the determination of postoperative mortality and morbidity including AKI\textsuperscript{13}.

**Risk Factors**

There are several possible causes of AKI after open heart surgery, which can be classified as prerenal, renal, and postrenal causes. They can be further divided into: inflammatory, hemodynamic, constitutional and nephrotoxic (Table 2)\textsuperscript{16}. Of them, renal perfusion deficiency subjected to sustained hypotension during the perioperative period was considered to be the main cause of AKI after cardiac surgery\textsuperscript{17}. In a retrospective study on 108 patients with AKI after cardiac surgery, the etiologies responsible for the development of AKI included cardiogenic hypotension (46.3%, 50/108), multiorgan failure (2.8%, 3/108) (two were due to drug renal toxicity), respiratory failure (3.7%, 4/108), hemolysis (7.4%, 8/108), drug-induced interstitial pneumonia (0.9%, 1/108), and unknown causes (38.9%, 42/108)\textsuperscript{18}. The predictive risk factors for postoperative severe renal insufficiency include age, gender, white blood cell count >12,000/mm\textsuperscript{3}, prior CABG, congestive heart failure, peripheral vascular disease, diabetes, hypertension, and preoperative intra-aortic balloon pump\textsuperscript{19}. In cardiopulmonary surgery, the four most important independent risk factors for postoperative AKI are old age, preoperative renal insufficiency, **Table 2.** Predictive risk factors of acute renal failure after cardiac surgery.

| Type                        | Risk factor                                      | Preoperative | Intraoperative | Postoperative |
|-----------------------------|--------------------------------------------------|--------------|----------------|---------------|
| Prerenal                    | Lack of renal reserve                             | •            | Renal perfusion deficiency | •            |
|                             | Renovascular disorder                             | •            | Renal perfusion deficiency | •            |
|                             | Prerenal azotemia                                 | •            | Renal perfusion deficiency | •            |
| 2. Hemodynamic              | Cardiac dysfunction                               | •            | Non-pulsatile flow | •            |
|                             | Cardiogenic shock                                 | •            | Vasoactive agents | •            |
|                             | Severe arrhythmias                                | •            | Anesthetic effects | •            |
|                             | Left main coronary disease                        | •            | Cardiogenic shock | •            |
| 3. Institutional            | Chronic obstructive pulmonary disease             | •            | Severe arrhythmias | •            |
|                             | Diabetes                                          | •            | Embolic events | •            |
|                             | Low serum ferritin                                 | •            | Positive end-expiratory pressure | •            |
| Renal                       | Lung disease                                      | •            | Acute lung injury | •            |
| 2. Inflammatory             | Inflammation                                      | •            | Ischemia-reperfusion injury | •            |
| 3. Endotoxic                | Endotoxemia                                       | •            | Surgical operation | •            |
| 4. Nephrotoxic              | Intravenous contrast                              | •            | Cardiopulmonary bypass | •            |
|                             | Angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II receptor antagonist (ARB) | •            | Systemic inflammation | •            |
|                             | Other medications                                 | •            | Ditto | •            |
| 5. Renal vascular and microvascular | Renal artery thrombosis                      | •            | Ditto | •            |
|                             | Takayasu arteritis involving the renal artery     | •            | Ditto | •            |
|                             | Renal vein thrombosis                             | •            | Ditto | •            |
|                             | Disseminated intravascular coagulation            | •            | Ditto | •            |
| Postrenal                   | Renal pelvic and ureteropelvic junction obstruction (renal calculus, malignant tumors, pelvic and retroperitoneal tumor compression) | •            | Ditto | •            |
|                             | Urocytic unfluent urination (prostatic hyperplasia or tumor, sarcoma, calculus and blood clots of the bladder, and neurogenic bladder) | •            | Ditto | •            |
|                             | Urethral stricture                                | •            | Ditto | •            |
Except for the conventional indicators, such as serum creatine, GFR, and cystin C, etc., a series of novel biomarkers have been favored in the assessment of AKI after cardiac surgery. These biomarkers, including urinary liver-type fatty acid binding protein (L-FABP), urinary neutrophil gelatinase-associated lipocalin (NGAL), and serum L-FABP, slightly increased in patients who did not develop AKI after cardiac surgery, but the increments were significant in patients with postoperative AKI (Figure 2) [28]. It was demonstrated that urinary L-FABP closely correlated to renal ischemia, namely, peritubular capillary ischemia, and might predict and survey the progression and prognosis of renal disorder, and therefore it was regarded as a reliable indicator of AKI, which precedes serum creatinine by hours to days [28]. The NGAL is an early indicator of renal ischemia and toxic injuries, and it is remarkably increased in both serum and urine in cases of AKI [29]. Pickering et al. [30] defined the cutoff for structural AKI as a urinary NGAL concentration >18.7 ng/mL. The areas under curve (AUCs) of plasma NGAL were 0.74 for the diagnosis of functional AKI, 0.79 for the diagnosis of structural AKI, 0.79 for the diagnosis of AKI and for prediction of renal replacement therapy, and 0.58 for the prediction of death.

L-FABP, a 14-kDa fatty acid binding protein, is elevated and secreted into the urine as a result of reactive oxygen stress due to renal ischemia. It has been used as a biomarker for the early detection of AKI after cardiac surgery. Urinary L-FABP levels were 601.5±341.7 and 233.8±127.2 μg/g Cr in the AKI and non-AKI groups, respectively, at the end of surgery. Three hours after surgery, urinary NGAL levels were 950.5±827.9 and 430.0±250.6 μg/g Cr in the AKI and non-AKI groups, respectively (P<0.05) [31].

Fig. 1 – A conceptual model of the pathophysiology of acute kidney injury after cardiac surgery.

BP=blood pressure; GFR=glomerular filtration rate; RAS=renin-angiotensin system; SAS=sympathetic-adrenomedullary system
Heart-type FABP (h-FABP) is a biomarker for myocardial ischemia and is associated with electrocardiogram changes, arrhythmias, and mortality after cardiac surgery. h-FABP and log(h-FABP) levels were discovered to correlate with the severity of AKI, and one unit increase in log(h-FABP) was associated with a threefold increase in the odds of developing AKI\(^{[32,33]}\). Oezkur et al.\(^{[34]}\) reported that h-FABP was much higher in the AKI than in the non-AKI group (2.9 ng/mL vs. 1.7 ng/mL, \(P=0.04\)). Preoperative h-FABP correlated closely with the length of intensive care unit stay (\(r=0.32, P=0.007\)) and with duration of hospitalization (\(r=0.308, P=0.009\)). Moreover, h-FABP was significantly associated with preoperative creatinine, eGFR, and myoglobin levels.

Kidney injury molecule 1 (KIM-1) is a type-1 transmembrane glycoprotein typically expressed in the proximal tubule cells in ischemic and nephrotoxic conditions. Pediatric patients undergoing cardiac surgery with AKI had higher levels of KIM-1 than the controls, and 12, 24, and 36 hours after CPB, the AUCs for the diagnosis of AKI by using KIM-1 were 0.83, 0.78, and 0.84, respectively\(^{[35]}\). As reported by Parikh et al.\(^{[36]}\), postoperative KIM-1 levels were significantly increased in comparison to preoperative baselines in both adult and pediatric patients (Figure 3). But KIM-1 was noted to be of no value in predicting progression of the renal disease as L-FABP\(^{[36]}\). Instead, urinary KIM-1 levels predicted dialysis requirement and mortality\(^{[37]}\). However, Parikh et al.\(^{[36]}\) indicated that KIM-1 functions to predict progression of AKI and adverse outcomes (dialysis requirement and death).

**Fig. 2** – A comparison of novel biomarkers between acute kidney injury (AKI) and non-AKI patients: (A) urinary L-FABP, (B) urinary NGAL, and (C) serum L-FABP were significantly higher in AKI than in non-AKI patients at 4 and 12 hours postoperatively. **\(P<0.01\) between AKI and non-AKI patients.

L-FABP = liver-type fatty acid binding protein; NGAL = neutrophil gelatinase-associated lipocalin

**Fig. 3** – A comparison of kidney injury molecule 1 (KIM-1) between acute kidney injury (AKI) and non-AKI patients during postoperative period: (A) in adult and (B) in pediatric patients. *\(P<0.05\) between AKI and non-AKI patients.
They also proposed combined biomarkers (urine KIM-1 on day 1 plus plasma NGAL on day 2, or urine KIM-1 on day 1 plus urine interleukin [IL]-18 on day 2 plus plasma NGAL on day 3) for more accurate predictive outcomes.

Urinary IL-18 levels were significantly increased in patients with AKI compared to controls. Also, urinary IL-18 was increased in kidney transplant patients who had delayed kidney graft function[48]. Parikh et al.[39] observed that IL-18 increased 4-6 hours after CPB, peaked at a 25-fold increase at 12 hours, and remained markedly elevated up to 48 hours after CPB; urinary NGAL at 4 hours and IL-18 at 4 hours had the best correlation with days of AKI. They suggested that IL-18 is an early, predictive biomarker of AKI after CPB. However, in a single-centre prospective observational cohort study, Haase et al.[40] proposed a dissenting opinion and argued that IL-18 is useless for predict AKI as they noted that urinary IL-18 at 24 hours postoperatively in patients who developed AKI after cardiac surgery was not different from that of non-AKI patients.

Two biomarkers, tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7), are both inducers of the G1 cell cycle arrest and have recently been applied in clinical practice for the early detection of AKI in critical patients[41]. Analyses of [TIMP-2]*[IGFBP7] on day 1 after transaortic valve implantation revealed a sensitivity of 100% and a specificity of 90% for predicting AKI 2/3. Patients with urinary [TIMP-2]*[IGFBP7] >0.3 had seven times the risk for AKI compared to those critical patients with a result <0.3[41].

Plasma growth-differentiation factor-15 (GDF-15) can be significantly higher in patients with AKI than in those without it[42]. Heringlake et al.[42] proposed that the plasma level of GDF-15 was a postoperative predictive indicator of AKI. This indicator also predicts postoperative mortality and stratifies patients' risks. However, further investigations are required.

**TREATMENT**

**Pharmaceutical Strategies**

Diuretics (e.g., mannitol and furosemide): The rationale of AKI treatment by improving renal blood flow and reducing tubular reabsorption is a logical approach for the prevention of outer medullary hypoxic injury. The loop diuretic furosemide acts on the sodium-chloride-potassium co-transporters at the intraluminal side of the ascending limb of the loop of Henle[43]. It has been shown to reduce medullary demand by inhibiting solute reabsorption and to attenuate the severity of AKI in animal models[44]. Furosemide can increase urine output without improving the creatinine clearance, renal function, and ototoxicity from furosemide because the clearance of furosemide increases the precipitation of urinary glycoprotein by inducing aciduria[43]. Treatment with mannitol in patients with cardiac surgery may increase urine flow by 61%, increase renal blood flow by 12%, and decrease renal vascular resistance by 13%[45].

Vasoactive agents (e.g., calcium channel blockers and atrial natriuretic peptide): The protective effect of calcium channel blockers on both the ischemic and nephrotoxic models of AKI is a potential role for cellular and mitochondrial calcium overload during reperfusion[46]. In healthy volunteers and in patients after cardiac surgery with normal renal function, the natriuretic response to atrial natriuretic peptide is associated with an increase in the GFR as evidenced by the majority of studies. At a normal infusion rate, the GFR and filtration fraction increase by 5-35% and 20-60%, respectively. In ischemic AKI, atrial natriuretic peptide preferentially induces a reduction in preglomerular resistance. Atrial natriuretic peptide plays an important part in theafferent arterioles in terms of its renal vasodilatory effect in clinically ischemic acute renal failure[47].

Dopamine: Low-dose (1-3 μg/kg/min) dopamine can increase the renal perfusion of critically ill patients[48]. However, it was reported that a continuous intravenous infusion of low-dose dopamine (2 μg/kg/min) did not show significant protection from renal dysfunction[49]. Recent studies have indicated that low-dose dopamine may also be deleterious as a result of inducing renal failure as it may reduce splanchnic perfusion, depress respiration, suppress anterior pituitary hormone release and function, and worsen renal function in hypovolemic or normovolemic patients[50].

Dopamine receptors (dopamine-1 and dopamine-2): Selective dopamine-1 agonists have many desirable renal effects that theoretically support their use for the prophylaxis and (or) treatment of AKI for decreasing renal vascular resistance and increasing sodium excretion and urine volume. Even at high doses, some selective dopamine-1 agonists, such as fenoldopam, do not stimulate dopamine-2 receptors, or adrenergic α- or β-receptors, and therefore they are free of unwanted side effects (e.g., arrhythmias)[51]. Selective dopamine-1 receptor agonists exhibit many renal effects in decreasing renal vascular resistance and increasing renal blood flow, glomerular filtration, and sodium and water excretion[52].

Steroids: Steroid therapy (prednisolone 1 mg/kg for 1 month, tapered off 0.1 mg/kg every two weeks) in patients with moderate renal failure and evidence of renal functional deterioration retards the progression of renal failure characterized by an interstitial fibrosis[53]. However, the anti-inflammatory agents, such as dexamethasone, administered before the start of CPB, showed no protective effect on perioperative renal dysfunction in low-risk cardiac surgical patients[54].

Antioxidant (N-acetylcysteine [NAC]): NAC does not reduce the extent of proximal tubule necrosis in 24 hours after reperfusion but may improve the histological appearance of the kidney in 7 days. This improvement of renal function impairment may be attributable to the NAC antioxidant effect or possible interactions between NAC and nitric oxide[55], and it can decrease the creatinine level significantly after the treatment[56]. However, Adabag et al.[57] raised a different opinion, that prophylactic NAC management prior to cardiac surgery did not reduce AKI incidence or decrease creatinine increase after surgery. In a recent prospective randomized study, Amini et al.[58] found out that perioperative use of NAC, vitamin C, and selenium, did not reduce the risk of AKI following off-pump coronary artery bypass procedure.

**Renal Replacement Therapy**

The internal jugular and femoral veins are the usual venous accesses for cannulations of renal replacement therapy. The
Prognosis

Patients with postoperative AKI were associated with a much higher mortality rate in comparison to those without it (18.8% vs. 2.1%). It has been shown that the mortality was 50% in the patients who needed dialysis[60]. Silva et al.[61] proved in a retrospective study that AKI patients requiring dialysis during postoperative period were a risk factor of late mortality. Zheng et al.[9] reported that patients with oliguresis of 3 hours showed a higher drug cure rate and a lower mortality rate than those with oliguresis >5-6 hours (drug cure rate: 75.8% vs. 17.6%; mortality rate: 3.0% vs. 47.1%; respectively). Han et al.[10] found out that the survival rate of patients with oliguric AKI was significantly lower than that of those with non-oliguric AKI. Oliguric AKI, along with sustained hypotension, number of failure organs, and dialysis requirement, was a risk factor closely related to mortality. Demirkiliç et al.[59] reported that continuous venousous hemodiafiltration was used in patients with creatinine level >5 mg/dL or potassium level >5.5 mEq/L, with no response to diuretics. The intensive care unit mortality rate was 48.1% for patients with an early start dialysis on day 0.88±0.33 and 17.6% for those with a late start dialysis on day 2.56±1.67. Thus, an early dialysis for AKI after cardiac surgery is associated with significant lower hospital mortality.

Pediatric patients with postoperative AKI following correction of congenital heart defect under CPB can be treated by peritoneal dialysis[62]. In such patient population with renal replacement therapy, the mortality rate varied between 33% and 70%. This occurred because children have immaturely developed organ system, with poor physiological reserve and compensatory ability, and impaired tolerance to ischemia and hypoxia. Comparative studies revealed that continuous arteriovenous hemofiltration and continuous venousous hemofiltration were mostly used in adults, requiring additional blood circuit and system heparinization; while peritoneal dialysis was commonly used for infantile AKI, but no significance was noted in the mortality rates between these groups. Peritoneal dialysis can remove excess water from the body and adjust disturbance of water and electrolyte and acid-base imbalance. Also, peritoneal dialysis shows little influence on hemodynamics, particularly on low output syndrome after open heart surgery, as this kind of dialysis does not require cannulation and systemic heparinization. Peritoneal dialysis is extremely suitable for AKI after open heart surgery in children for renal replacement therapy as for the simple devices and fewer maneuver requirements[63].

CONCLUSION

In patients with AKI after cardiac surgery, novel biomarkers have been recognized as reliable indicators for diagnosis, predicting the adverse outcome, and even mortality of postoperative AKI. Renal replacement therapy should start early to achieve a promising prognosis. In children, AKI after cardiac surgery can be managed with peritoneal dialysis, which may benefit them with better hemodynamic stability.

REFERENCES

1. Bove T, Calabrò MG, Landoni G, Alettì G, Marino G, Crescenzì G, et al. The incidence and risk of acute renal failure after cardiac surgery. J Cardiothorac Vasc Anesth. 2004;18(4):442-5. doi: 10.1053/j.jvca.2004.05.021.
2. Stallwood MI, Grayson AD, Mills K, Scawn ND. Acute renal failure in coronary artery bypass surgery: independent effect of cardiopulmonary bypass. Ann Thorac Surg. 2004;77(3):968-72. doi:10.1016/j.athoracsur.2003.09.063.
3. Niccolà A, Patel UD, Phillips-Bute BG, Shaw AD, Stafford-Smith M, Miliano CA, et al. Mortality trends associated with acute renal failure requiring dialysis after CABG surgery in the United States. Blood Purif. 2009;28(4):359-63. doi:10.1159/000235856.
4. Barbosa RR, Cestari PF, Capeletti JT, Peres GM, Ibañez TL, da Silva PV, et al. Impact of renal failure on in-hospital outcomes after coronary artery bypass surgery. Arq Bras Cardiol. 2011;97(3):249-53. doi:10.1590/S0066-782X2011000000075.
5. King KB, Clark PC, Noren LH, Hicks GL Jr. Coronary artery bypass graft surgery in older women and men. Am J Crit Care [Internet]. 1992 [cited 2019 Apr 25];1(2):28-35. Available from: https://www.ncbi.nlm.nih.gov/pubmed/1307888.
6. Gargiulo G, Sannino A, Capodanno D, Barbanti M, Buccheri S, Perrino C, et al. Transcatheter aortic valve implantation versus surgical aortic valve replacement: a systematic review and meta-analysis. Ann Intern Med. 2016;165(5):334-44. doi:10.7326/M16-0060.
7. Ko T, Higashitani M, Sato A, Uemura Y, Norimatsu T, Mahara K, et al. Impact of acute kidney injury on early to long-term outcomes in patients who underwent surgery for type A acute aortic dissection. Am J Cardiol. 2015;116(3):463-8. doi:10.1016/j.amjcard.2015.04.043.
8. Ng RR, Tan GH, Liu W, Ti LK, Chew ST. The association of acute kidney injury and atrial fibrillation after cardiac surgery in an Asian prospective cohort study. Medicine (Baltimore). 2016;95(12):e3005. doi:10.1097/MD.0000000000003005.
9. Zheng ZF, Qiu ZK, Gong BS, Ren SN. Treatment of acute renal failure complicating cardiac surgery. Shanghai Med J. 2002;25(1):29-32.
42. Heringlake M, Charitos EI, Erber K, Berggreen AE, Heinze H, Paarmann H. Preoperative plasma growth-differentiation factor-15 for prediction of acute kidney injury in patients undergoing cardiac surgery. Crit Care. 2016;20(1):317. doi:10.1186/s13054-016-1482-3.

43. Ho KM, Power BM. Benefits and risks of furosemide in acute kidney injury. Anaesthesia. 2010;65(3):283-93. doi:10.1011/j.1365-2044.2009.06228.x.

44. Davis A, Gooch I. The use of loop diuretics in acute renal failure in critically ill patients to reduce mortality, maintain renal function, or avoid the requirements for renal support. Emerg Med J. 2006;23(7):561-4. doi:10.1136/emj.2006.038513.

45. Bragadottir G, Redfors B, Ricksten SE. Mannitol increases renal blood flow and maintains filtration fraction and oxygenation in postoperative acute kidney injury: a prospective interventional study. Crit Care. 2012;16(4):R159. doi:10.1186/cc11480.

46. Chan L, Schrier RW. Effects of calcium channel blockers on renal function. Annu Rev Med. 1990;41:289-302. doi:10.1146/annurev.me.41.020190.001445.

47. Ricksten SE, Swärd K. Atrial natriuretic peptide in postoperative acute renal failure. In: Vicent JL, editor. Intensive Care and Emergency Medicine. New York: Springer; 2010. p. 339-48. doi:10.1007/978-3-642-10286-8_32.

48. Fry AC, Farrington K. Management of acute renal failure. Postgrad Med J. 2006;82(964):106-16. doi:10.1136/pmg.2005.035858.

49. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 2000;356(9248):2139-43. doi:10.1016/S0140-6736(00)03495-4.

50. Debaveye YA, Van den Berghe GH. Is there still a place for dopamine in the modern intensive care unit? Anesth Analg. 2004;98(2):461-8. doi:10.1213/01.ANE.0000096188.35789.37.

51. Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis. 1998;31(5):743-55. doi:10.1016/S0272-6386(98)70043-5.

52. Asif A, Epstein DL, Epstein M. Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy. J Clin Pharmacol. 2004;44(12):1342-51. doi:10.1177/0091270004269842.

53. Vanherweghem JL, Abramowicz D, Tielemans C, Depierreux M. Effects of steroids on the progression of renal failure in chronic interstitial renal fibrosis: a pilot study in Chinese herbs nephropathy. Am J Kidney Dis. 1996;27(2):209-15. doi:10.1016/S0272-6386(96)90542-9.

54. Loef BG, Henning RH, Epema AH, Rietman GW, van Oeveren W, Navis GJ, et al. Effect of dexamethasone on perioperative renal function impairment during cardiac surgery with cardiopulmonary bypass. Br J Anaesth. 2004;93(6):793-8. doi:10.1093/bja/aeh266.

55. DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R. N-acetyl cysteine ameliorates ischemic renal failure. Am J Physiol. 1997;272(3 Pt 2):F292-8. doi:10.1152/ajprenal.1997.272.3.F292.

56. Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med. 2006;166(2):161-6. doi:10.1001/archinte.166.2.161.

57. Adabag AS, Ishani A, Bloomfield HE, Ngo AK, Wilt TJ. Efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a systematic review of randomized trials. Eur Heart J. 2009;30(15):1910-7. doi:10.1093/eurheartj/ehp053.

58. Amini S, Robabi HN, Tashnizi MA, Vakili V. Selenium, vitamin C and N-acetylcysteine do not reduce the risk of acute kidney injury after off-pump CABG: a randomized clinical trial. Braz J Cardiovasc Surg. 2018;33(2):129-34. doi:10.21470/1678-9741-2017-0071.

59. Demirkiliç U, Kuralay E, Yenicesu M, Cağlar K, Öz BS, Cingöz F, et al. Timing of replacement therapy for acute renal failure after cardiac surgery. J Card Surg. 2004;19(1):17-20. doi:10.1111/j.0886-0440.2004.00404.x.

60. Chan L, Schrier RW. Effects of calcium channel blockers on renal function. Annu Rev Med. 1990;41:289-302. doi:10.1146/annurev.me.41.020190.001445.